DROnedARONE For Atrial Fibrillation
By David A. Sandler, MD, FACC

TREATMENT OPTIONS FOR CHRONIC VENOUS DISEASE
By Robert Smith, Jr., MD, MSc, FACC, FSCAI

PRASUGREL: A NEW THIRD-GENERATION THIENOPYRIDINE
By Greg Johnsen, MD, FACC, FSCAI
OUR FOCUS IS ON HEALTHCARE

- Real Estate & Equipment Financing
- Lines of Credit
- Start-up Practice Financing
- Cash Management Services
- SNB Digital Lockbox
- Healthcare Consulting Services
- Rural Healthcare Lending

www.banksnb.com/medical

Oklahoma Texas Kansas

Since 1894 • 888.762.4762 • Member FDIC
4 To Our Readers

5 Dronedarone for Atrial Fibrillation

8 Treatment Options for Chronic Venous Disease

17 Prasugrel: A New Third-Generation Thienopyridine

22 The Power of Positive Habits

“Heartfelt Reflections” by Tulsa Artist Christopher Westfall
12” x 16” Acrylic

OKLAHOMA HEART INSTITUTE
THE HEART HOSPITAL
1120 Utica Avenue
Tulsa, OK 74104
Phone: 918.574.9000

OKLAHOMA HEART INSTITUTE AT UTICA
PHYSICIANS OFFICES
1265 S. Utica Avenue
Suite 300
Tulsa, OK 74104
Phone: 918.592.0999
Fax: 918.592.1021

OKLAHOMA HEART INSTITUTE
AT SOUTHPOINTE
PHYSICIANS OFFICES
9228 S. Mingo
Suite 200
Tulsa, OK 74133
Phone: 918.592.0999
Fax: 918.878.2499

THE DOCTORS OF OKLAHOMA
HEART INSTITUTE
Wayne N. Leimbach Jr., MD
Robert C. Sonnenschein, MD
Robert E. Lynch, MD
James J. Nemec, MD
Gregory D. Johnsen, MD
Alan M. Kaneshige, MD
Edward T. Martin, MD
Roger D. Des Prez, MD
Christian S. Hanson, DO
Rebecca L. Smith, MD
Tobie L. Bresloff, MD
David A. Sandler, MD
Raj H. Chandwaney, MD
D. Erik Aspengren, MD
Frank J. Gaffney, MD
Eric G. Auerbach, MD
Kelly R. Flesner, MD
Robert L. Smith Jr., MD, M.Sc.
Craig S. Cameron, MD
Eugene J. Ichinose, MD
Cristin M. Bruns, MD
Gregory A. Cogert, MD
John S. Tulloch, MD
Anthony W. Haney, MD

Oklahoma Heart Institute
The Oklahoma Heart Institute Magazine is mailed directly to referring physicians and other referring health care professionals in the Tulsa area and is also available in our patient waiting areas.

Created by Publishing Concepts, Inc.
Virginia Robertson, Publisher • vrobertson@pcipublishing.com
14109 Taylor Loop Road • Little Rock, AR 72223 / 501.221.9986 / 800.561.4686
For advertising information contact: Suzanne Ramsel at 501.221.9986 or 800.561.4686
sramsel@pcipublishing.com visit our website www.pcipublishing.com
Edition 16
ONE OF THE EXCITING THINGS ABOUT THE FIELD OF CARDIOLOGY is the newer treatment options that continue to become available. In this issue of Oklahoma Heart Institute Magazine, some of the newest pharmacologic agents that have been approved, or are expected to be approved, are discussed. Dr. Sandler, Director of Electrophysiology at Oklahoma Heart Institute, discusses the background information, the therapeutic efficacy, and the side effects of the recently approved anti-arrhythmic agent dronedarone. Dronedarone was recently approved for the treatment of atrial fibrillation. Dronedarone has many of the advantages of amiodarone, but without the significant side effects.

Dr. Greg Johnsen, an interventional cardiologist at Oklahoma Heart Institute, discusses the information leading to the approval of prasugrel (Effient), which is a new anti-platelet agent similar to clopidogrel, but without the concerns of patients being resistant to the medication.

Finally, Dr. Robert Smith, an invasive cardiologist at Oklahoma Heart Institute and Director of the Venous Clinic at Oklahoma Heart Institute, describes the treatment options for chronic venous disease. Peripheral venous disease is four to five times more prevalent than peripheral arterial disease. Although peripheral venous disease is less likely to affect mortality, it is a major factor affecting the quality of life for many patients.

We hope you enjoy these articles and welcome any comments or suggestions regarding the magazine content.

Sincerely,
Wayne N. Leimbach Jr., MD,
Editor, Oklahoma Heart Institute Magazine
BACKGROUND
On July 2, 2009, the FDA approved dronedarone (Multaq) for prevention of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation associated with cardiovascular risk factors. This new oral anti-arrhythmic agent is the first to be approved by the FDA in 10 years.

To understand the role of this drug, it is important to review the current state of AF management. The first branch in the decision tree of AF management is the strategy of rhythm control (ie: anti-arrhythmic medications, cardioversion, AF ablation, etc) versus rate control (leaving the patient in AF and controlling rate alone). AFFIRM was a large multicenter trial demonstrating that these two strategies offered similar outcomes in a population of minimally symptomatic AF patients with an average age of 69. Therefore, a strategy of rhythm control in asymptomatic or minimally symptomatic patients has been discouraged.

On the other hand, restoration of sinus rhythm in patients with AF has been demonstrated to improve left ventricular ejection fraction, left atrial size, and quality of life both in patients with congestive heart failure and normal ejection fraction, even when optimal ventricular rate control during AF has been achieved.

In fact, review of AFFIRM demonstrates a mortality benefit in patients who were able to maintain sinus rhythm. This benefit, however, was negated by the increased mortality associated with anti-

DRONEDARONE FOR ATRIAL FIBRILLATION

Table 1
Oral Antiarrhythmic Medications Listed Alphabetically by Class

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class Ic</td>
<td></td>
</tr>
<tr>
<td>Flecainide</td>
<td>Tambocor</td>
</tr>
<tr>
<td>Propafenone</td>
<td>Rythmol, Rythmol SR</td>
</tr>
<tr>
<td>Class III</td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Cordarone, Pacerone</td>
</tr>
<tr>
<td>Dofetilide</td>
<td>Tikosyn</td>
</tr>
<tr>
<td>Dronedarone</td>
<td>Multaq</td>
</tr>
<tr>
<td>Sotalol</td>
<td>Betapace, Betapace AF</td>
</tr>
</tbody>
</table>

Note: Some drugs (particularly amiodarone, dronedarone, and sotalol) share properties of other classes; the drugs are listed by class of their predominant effect.

Table 2
Side-Effects of Dronedarone Requiring Discontinuation in the ADONIS/EURYDIS Trials

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=2875)</th>
<th>Dronedarone (n=3282)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6%</td>
<td>9%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Dyspeptic signs and symptoms</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>General</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic conditions</td>
<td>5%</td>
<td>7%</td>
</tr>
<tr>
<td>Cardiac</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradycardia</td>
<td>1%</td>
<td>3%</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue</td>
<td>3%</td>
<td>5%</td>
</tr>
</tbody>
</table>

On the other hand, restoration of sinus rhythm in patients with AF has been demonstrated to improve left ventricular ejection fraction, left atrial size, and quality of life both in patients with arrhythmic medications. In other words, the medications used to treat AF seem to carry side effects, which counteract any benefit obtained from maintaining sinus rhythm.

continued on page 6
The current ACC/AHA/ESC AF Management Guidelines for maintaining sinus rhythm are summarized in Figure 1. A list of anti-arrhythmic medications recommended for AF (with generic and trade names) is listed in Table 1. Each of these agents has limitations. Propafenone and flecainide have limited use due to risk of increased mortality in patients with coronary artery disease or congestive heart failure. Sotalol and dofetilide each carry a risk of QT prolongation leading to torsades de pointes. In addition, each of these medications is contraindicated in patients with renal insufficiency.

The most effective anti-arrhythmic for AF is amiodarone (ironically, without an FDA indication for AF). Unfortunately, this medication is limited by its side effects. Specifically, pulmonary fibrosis, thyroid dysfunction, liver failure and skin discoloration result in significant rates of withdrawal. Each of these side effects is attributed to the iodine moiety in the chemical composition.

Large randomized trials have demonstrated that dronedarone is a safe alternative to the more commonly prescribed antiarrhythmic agents on the market. The trade-off of this safety is lower efficacy in preventing AF recurrence.

Dronedarone has a chemical composition similar to amiodarone, but lacks the iodine moiety. The goal, of course, is to harness the efficacy of amiodarone without the side effects. This drug prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty

and has been the subject of numerous clinical studies evaluating efficacy and safety.

THE TRIALS
The ATHENA Trial was the largest dronedarone trial and included 4,638 patients with risk factors for stroke (age ≥ 75 or age ≥ 70 with hypertension, diabetes, left atrial enlargement, ejection fraction < 40 percent or prior TIA/stroke) randomized to dronedarone or placebo. In these patients dronedarone was associated with a 24 percent reduction in death or cardiovascular hospitalization (Figure 2). Oklahoma Heart Institute was a participant in ATHENA, and we are grateful to our patients for partnering with us in this landmark trial.

The ANDROMEDA Trial was designed to evaluate potential benefit of dronedarone on all-cause mortality or hospitalization for worsening heart failure. The study enrolled 627 patients with relatively severe heart failure who had been hospitalized or referred to a specialty
clinic for worsening symptoms of heart failure. This trial was terminated prematurely when the Data Safety and Monitoring Board detected a greater than two-fold increase in mortality in dronedarone group. For this reason, dronedarone should not be prescribed to patients with NYHA Class IV heart failure or Class II-III with recent decompensation.

The EURIDIS/ADONIS Trials enrolled a total of 1,237 patients with ≥1 documented episode in the prior three months. In these patients, there was a 25 percent reduction in the risk of recurrent AF.

The DIONYSOS Trial pit dronedarone against amiodarone in 504 patients. This as-of-yet unpublished trial demonstrated a significantly higher rate of AF recurrence with dronedarone (63 percent vs 42 percent) with a trade-off of fewer adverse effects.

A recent meta-analysis reviewed studies of dronedarone or amiodarone. Amiodarone was shown to reduce AF recurrence more effectively than dronedarone. However, adverse effects were higher with amiodarone, and a trend towards improved mortality was seen with dronedarone.

CONTRAINDICATIONS/ADVERSE REACTIONS

Dronedarone is contraindicated in patients with NYHA Class IV heart failure or Class II-III with recent decompensation (based on the ANDROMEDA Trial). Severe liver failure, bradycardia (<50 bpm), QTc >500ms are also reasons to avoid dronedarone. Drugs that prolong QT or inhibit CYP 3A should be avoided with dronedarone. Digoxin should be avoided, or at least halved. (As always, please review package insert prior to prescribing any new drug).

Adverse reactions of dronedarone are listed in Table 2. Notably, gastrointestinal complaints appear common with this medication. Fortunately, serious side effects such as pulmonary fibrosis, torsades de pointes and hepatic failure appear to be extremely rare.

SUMMARY

Dronedarone is a new antiarrhythmic drug indicated for prevention of cardiovascular hospitalization in patients with AF and risk factors for stroke. Large randomized trials have demonstrated that dronedarone is a safe alternative to the more commonly prescribed antiarrhythmic agents on the market. The trade-off of this safety is lower efficacy in preventing AF recurrence.

Whether this new, safer agent will shift the paradigm of rate control versus rhythm control will be tested in the future.

REFERENCES
ACC/AHA/ESC 2006 Atrial Fibrillation Guidelines J Am Coll Cardiol, 2006; 48:149-246

De Dr. David Sandler is a cardiologist with specialty expertise in electrophysiology, complex ablation and atrial fibrillation management.
ALTHOUGH RECENT YEARS have brought about a greater awareness of the importance of diagnosing and treating peripheral arterial disease, pathology of the venous system has received little attention. Peripheral venous disease was first mentioned in the medical literature in 500 BC, when Hippocrates described an association between leg ulcers and varicose veins. Despite longstanding recognition, understanding of issues surrounding venous hypertension and resultant venous incompetence has lagged.

Peripheral venous disease is four to five times more prevalent than peripheral arterial disease, and the clinical presentation of lower extremity venous incompetence spans a broad clinical spectrum from telangiectasias (spider veins) to long-standing and recalcitrant venous stasis ulcers. This spectrum of disease manifests from cosmetically displeasing lesions on the legs to threats of serious secondary illnesses such as DVT/PE and infection from chronic ulceration. Venous disease has a hereditary component, and children of patients with varicose veins are more likely to develop problems related to venous reflux. Occupations characterized by inactivity, such as standing or sitting for long periods of time, also place patients at risk.

Traditionally, treatment of venous incompetence has consisted mainly of surgical “vein stripping” procedures,

---

**Figure 1**
Veins of the Deep and Superficial Venous Systems of the Lower Extremity

**Figure 2**
Flow of Venous Blood from the Deep System to the Heart is Aided by the Pumping of the Calf Muscles, Which Actively Propels Blood Against Gravity with Each Contraction.
during which large veins from the superficial collecting system of the legs are ligated and/or removed under general anesthesia. These surgical procedures, while effective, are associated with the risks of general anesthesia, infection of surgical wounds, long recovery times, and considerable patient discomfort. Perhaps for these reasons, surgical treatment of venous disease has occupied a rather small niche, and many patients have chosen to live with the condition rather than opt for surgery.

In order to understand the physiology of venous reflux disease, one must understand that there are two distinct venous systems in the lower extremities: the deep venous system is comprised of veins that run parallel to the arteries. These veins are surrounded by muscle and encased in fascia, providing them with good mechanical support. The deep veins are responsible for returning >95 percent of the venous blood from the lower extremity back to the heart. The superficial system, comprised of the saphenous veins, perforator veins, and tributaries, lies just beneath the skin and is without the mechanical support of the deep system. These superficial veins collect blood from surrounding tissues and, in a healthy system, route blood into the deep system so that it may be returned to the heart (Figure 1). It is typically incompetence of the superficial system that gives rise to the clinical sequelae of venous reflux disease.

It is widely accepted that the genesis of common manifestations of venous disease relates to incompetence of the greater saphenous vein, the largest superficial vein. In some cases, the small saphenous vein (previously referred to as the lesser saphenous vein) is also involved. These superficial veins are located about a centimeter beneath the skin and should be less than 3mm in diameter in a healthy patient, though they can dilate to greater than 10mm in a patient with venous reflux disease. Unlike the deep venous system, where contraction of the leg muscles plays an important role in “pumping” the venous blood back to the heart, the return of venous blood in the superficial systems is passive and depends entirely upon a series of one-way valves that aid the flow of the superficially collected blood on its route back to the deep venous system. Once in the deep system, venous blood is actively propelled against gravity back to the heart, primarily through the action of the calf muscles (Figure 2). In a healthy system, the superficially collected blood enters the deep venous system at two critical anatomic locations: the small saphenous vein deposits blood into the deep system at the sapheno-popliteal junction (near the knee) and the greater saphenous vein deposits blood into the deep system at the sapheno-femoral junction (near the groin). Additionally, smaller veins (called perforator veins) communicate between the superficial and deep systems throughout the length of their parallel course. These smaller perforator veins also have one-way valves that assist in the return of superficially collected blood back to the deep system. If the series of one-way valves in the superficial veins (and/or perforator veins) become incompetent (Figure 3), the superficial system becomes congested, and the flow of blood into the deep system (and subsequently toward the heart) stalls, resulting in edema, pain, and other clinical sequelae. When valvular function in the superficial system

continued on page 10
becomes sufficiently compromised, deoxygenated venous blood flows backwards, from the deep system into the superficial system, at these critical anatomic points, resulting in a blind loop, where deoxygenated blood cycles endlessly from the deep system to the superficial system, back to the deep system, and so forth, never making it back to the heart. Common clinical manifestations of these events are edema, heaviness, throbbing, pain, varicosities (bulging tributaries of the overloaded superficial veins), and skin changes that occur as a result of the endless loop of oxygen and nutrient poor blood circulating throughout the lower extremity network of veins. At the extreme, refractory and painful venous ulcers develop.

Although incompetence of the one-way valves can occur at any point in the network, the most common site of incompetence is the sapheno-femoral junction (Figure 4), where superficially collected blood in the greater saphenous vein should drain into the femoral vein (of the deep system). When incompetence of the sapheno-femoral junction occurs, venous blood from the deep system, en route to the heart, is diverted from the (deep) femoral vein back into the (superficial) greater saphenous vein. This is typically the starting point of the pathologic cycle, and causes the greater saphenous vein to become increasingly engorged, setting off a cascade of events where superficial valves, unaided by the pumping function of the leg muscles, fail in a proximal to distal fashion until clinical manifestations develop. Surgical removal of a diseased greater saphenous vein is effective in the treatment of venous reflux disease because the most common site of retrograde flow from the deep to superficial system is eliminated and the blood has nowhere to go but up (and back to the heart). Experience with surgical removal of the greater saphenous vein goes back many decades. Surgical literature on the topic indicates that, regardless of the

---

**Figure 5**
The VNUS Closure Procedure
*Using the ClosureFAST™ Catheter*

Catheter positioned at highest treatment point

Vein treated in 7 cm vein segments

Catheter withdrawn from marker to marker

Until entire length of vein is treated

In minimally invasive radiofrequency (RFA) ablation of the greater saphenous vein, a small incision is made near the knee (lower left panel), and the RFA catheter is advanced to a level just distal to the sapheno-femoral junction (upper left panel). Radiofrequency waves are then applied in a segmental fashion, treating 7 centimeters of the vein at a time. Pullback of the catheter is performed and the treatment is repeated until the entire length of the desired segment of vein is treated (right panels).

(Image provided by VNUS Medical Technologies, Inc.)

---

**Figure 6**

Disposable catheter inserted into vein

Vein heats and collapses

Catheter withdrawn, closing vein

Using a radiofrequency ablation catheter, the diseased vein is cannulated and energy is applied from within, resulting in fibrotic obliteration of the vein. The result is functionally identical to surgical “vein-stripping” procedures, during which the vein is surgically removed under general anesthesia.

(Image provided by VNUS Medical Technologies, Inc.)

---

continued on page 15
SERVICES OF OKLAHOMA HEART INSTITUTE

Invasive Cardiology
- Cardiac Catheterization
- Coronary Angioplasty
- Multivessel Angioplasty and Stenting
- Atherectomy
- Rotablator Atherectomy
- Thrombolytic Therapy
- Coronary Stents
- Carotid Stenting
- Intravascular Ultrasound
- Intracardiac Ultrasound
- Myocardial Biopsy
- Pericardiocentesis
- Peripheral Angioplasty
- Peripheral Stents
- Percutaneous ASD Closures
- Percutaneous PFO Closures
- Impella Circulatory Support
- Therapeutic Hypothermia for Cardiac Arrest Patients
- Venous Radiofrequency Ablations

Noninvasive Cardiology
- CT Angiography
- CT Heart Scan
- Cardiac and Vascular Screening Services
- Nuclear Cardiology
- Echocardiography and Doppler Studies
- Nuclear and Echocardiographic Exercise and Pharmacological Stress Testing
- Transesophageal Echocardiography, Arterial Venous Peripheral Vascular Imaging and Doppler Studies
- Peripheral Arterial Doppler and Duplex Imaging
- Cardiovascular Magnetic Resonance Imaging
- External Counterpulsation (ECP) Therapy
- Transcranial Doppler
- Aquapheresis Therapy

Electrophysiology
- Electrophysiology Studies
- Ablation Therapy
- Pacemaker Implantation
- Pacemaker and Lead Extraction
- Pacemaker Programming
- Pacemaker Monitoring and Clinic
- Implantable Cardioverter Defibrillator (ICD) Replacement
- ICD and Hardware Removal
- ICD Programming
- ICD Monitoring and Clinic
- Holter Monitoring and Interpretation

30 Day Cardiac Event Monitors
- Implantation and Interpretation of Long-Term Heart Monitors
- Signal Averaged EKGs and Interpretation
- Head Up Tilt Testing and Interpretation
- Direct Current Cardioversion
- Antiarrhythmic Drug Loading and Monitoring

Metabolic Disorders
- Diabetes
- Thyroid
- Hypertension
- Other Endocrine Problems

Specialty Clinics
- Advanced Center for Atrial Fibrillation
- Dysrhythmia and Pacer Clinic
- Hypertension Clinic
- Adolescent and Adult Congenital Heart Clinic
- Lipid and Wellness Clinic
- Heart Failure Clinic
- Same Day Appointment Clinic
- Pre-Operative Clinic
- Center for the Treatment of Venous Disease

OKLAHOMA HEART INSTITUTE
(The Heart Hospital)
1120 S. Utica Avenue
Tulsa, OK 74104
Phone: 918.574.9000

OKLAHOMA HEART INSTITUTE AT UTICA/PHYSICIANS OFFICE
1265 S. Utica Avenue
Suite 300
Tulsa, OK 74104
Phone: 918.592.0999
Fax: 918.592.1021

OKLAHOMA HEART INSTITUTE AT SOUTHPOINTE/PHYSICIANS OFFICE
9228 S. Mingo
Suite 200
Tulsa, OK 74133
Phone: 918.592.0999
Fax: 918.878.2499
THE DOCTORS OF OKLAHOMA HEART INSTITUTE

Wayne N. Leimbach, Jr., MD, FACC, FSCAI, FCCP, FAHA
Dr. Leimbach is a specialist in interventional cardiology, including cardiac catheterization, coronary angioplasty, percutaneous closure of PFO & ASDs and related interventional procedures such as stents, atherectomy, laser, intravascular ultrasound imaging and direct PTCA for acute myocardial infarction. He is Chief of Cardiology at Hillcrest Medical Center, where he is also Director of the Cardiac and Interventional Laboratories at Hillcrest Medical Center. Dr. Leimbach is Co-Director of the Lipid and Wellness Clinic at Oklahoma Heart Institute. He is Director of the James D. Harvey Center for Cardiovascular Research at Hillcrest Medical Center, as well as Director of the Oklahoma Heart Research and Education Foundation. He also serves as Clinical Associate Professor of Medicine at the University of Oklahoma College of Medicine – Tulsa. Dr. Leimbach completed a Clinical Cardiology Fellowship and a Research Fellowship at the University of Iowa Hospitals and Clinics. He also completed his Internal Medicine Internship and Residency programs at Iowa, where he was selected Chief Resident in Medicine. He received his medical degree from Northwestern University in Chicago and his Bachelor of Science degree from the University of Michigan. Board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology

Robert C. Sonnenschein, MD, FACC, ASE, RVT
Dr. Sonnenschein specializes in echocardiography and noninvasive peripheral vascular imaging. He is Director of Peripheral Vascular Ultrasound Imaging at Hillcrest Medical Center and Oklahoma Heart Institute and serves as Clinical Associate Professor of Medicine at the University of Oklahoma College of Medicine – Tulsa. He completed his Cardiology Fellowship at the State University of New York Upstate Medical Center in Syracuse, where he also completed his Internal Medicine Internship and Residency programs. Dr. Sonnenschein received his medical degree from Rush Medical College in Chicago and his Bachelor of Arts degree from the University of Pennsylvania. Board certified in Internal Medicine, Cardiovascular Disease and Adult Echocardiography. Registered Vascular Technologist

Robert E. Lynch, MD, FACC
Dr. Lynch is a specialist in noninvasive and invasive cardiology with a special interest in the prevention of cardiovascular disease. He is former Chief of Cardiology at Hillcrest Medical Center, where he also has served as Chief of Medicine and President of the medical staff. Dr. Lynch is Co-Director of the Lipid and Wellness Clinic at Oklahoma Heart Institute and Director of the Executive Health Program. Dr. Lynch is also a Clinical Assistant Professor at the University of Oklahoma College of Medicine – Tulsa. He completed his Cardiology Fellowship, as well as his Internal Medicine Internship and Residency, at the University of Oklahoma Health Sciences Center. Dr. Lynch received his medical degree from the University of Oklahoma School of Medicine and his Bachelor of Science degree from the University of Tulsa. Before establishing his practice in Tulsa, he served as Chief of Medicine at the U.S. Army Hospital, Bangkok, Thailand. Board certified in Internal Medicine and Cardiovascular Disease

James S. Nemec, MD, FACC
Dr. Nemec is a specialist in echocardiography, stress echocardiography and nuclear cardiology. He serves as Director of Nuclear Cardiology for Oklahoma Heart Institute. Dr. Nemec has served as Assistant Professor of Internal Medicine, Division of Cardiology, at Creighton University and as Assistant Professor, Department of Radiology, also at Creighton University. He completed his Clinical Cardiology Fellowship at the Cleveland Clinic Foundation and his Internal Medicine Internship and Residency at Creighton University. Dr. Nemec also completed a year of training in pathology at the University of Missouri, Columbia, MO. He received his medical degree from Creighton University, where he also received his Bachelor of Arts degree. Board certified in Internal Medicine, Cardiovascular Disease and Nuclear Cardiology

Gregory D. Johnsen, MD, FACC, FSCAI
Dr. Johnsen is an interventional cardiologist with expertise in cardiac catheterization, angioplasty and related interventional procedures, such as stents and atherectomy. He is Director of Cardiac Rehabilitation at Hillcrest Medical Center and Director of the Hillcrest Exercise and Lifestyle Programs. He completed his Clinical Cardiology Fellowship at the University of Oklahoma – Oklahoma City, where he then finished an extra year of dedicated training in interventional cardiology. He completed his Internal Medicine Internship and Residency training at the University of Oklahoma – Oklahoma City, where he also received his medical degree. Dr. Johnsen received his Bachelor of Science degree from Oklahoma State University. Board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology

Alan M. Kaneshige, MD, FACC, ASE
Dr. Kaneshige is a noninvasive cardiologist with expertise in adult echocardiography, stress echocardiography and transesophageal echocardiography. He is past Chief of Cardiology at Hillcrest Medical Center. Dr. Kaneshige completed his Internal Medicine Internship and Residency at Creighton University School of Medicine, where he also received his medical degree. He received a Bachelor of Science in chemistry at Creighton University. Dr. Kaneshige completed his Clinical Cardiology Fellowship at Creighton, where he also served as Chief Cardiology Fellow for two years. He completed an additional Cardiac Ultrasound Fellowship at the Mayo Clinic in Rochester, MN. Dr. Kaneshige served as Assistant Professor of Medicine at Creighton University School of Medicine, where he was Director of the Noninvasive Cardiovascular Imaging and Hemodynamic Laboratory. Board certified in Internal Medicine, Cardiovascular Disease and Adult and Transesophageal Echocardiography

Edward T. Martin, MS, MD, FACC, FACP, FAHA
Dr. Martin is a noninvasive cardiologist with subspecialty expertise in noninvasive imaging. He is Director of Cardiovascular Magnetic Resonance Imaging at Oklahoma Heart Institute and Hillcrest Medical Center. In addition, he is a Clinical Associate Professor of Medicine at the University of Oklahoma College of Medicine – Tulsa. Dr. Martin has specialty training in Nuclear Medicine, as well as additional training dedicated to Cardiovascular Magnetic Resonance Imaging. He completed his Cardiology Fellowship at the University of Alabama. Dr. Martin’s Internal Medicine Internship and Residency training were performed at Temple University Hospital in Philadelphia. He received his medical degree from the Medical College of Ohio. Dr. Martin completed his Master of Science degree in mechanical engineering at the University of
of Cincinnati and his Bachelor of Science degree in physics at Xavier University. Dr. Martin is a founding member of the Society of Cardiovascular Magnetic Resonance and is an editorial board member of the Journal of Cardiovascular Magnetic Resonance.

Board certified in Internal Medicine and Cardiovascular Disease

Roger D. Des Prez, MD, FACC
Dr. Des Prez is a noninvasive cardiologist with subspecialty expertise in echocardiography, nuclear cardiology and cardiac computed tomography. He is Director of Cardiac Computed Tomography at Hillcrest Medical Center. Dr. Des Prez received his medical degree and Bachelor of Arts degree from Vanderbilt University. He completed his Residency in Internal Medicine and Pediatrics at University Hospital of Cleveland. Dr. Des Prez practiced for six years as an intern with the Indian Health Services in Gallup, NM. He returned to Vanderbilt University as a member of the Internal Medicine Faculty, at which time he also completed his cardiology training.

Board certified in Internal Medicine, Cardiovascular Disease, Echocardiography, Pediatrics and Nuclear Cardiology

Christian S. Hanson, DO, FACE
Dr. Hanson is a specialist in Endocrinology, Metabolism and Hypertension at Oklahoma Heart Institute with expertise in diabetes, lipids and hypertension. He also serves as Clinical Associate Professor of Medicine in the College of Osteopathic Medicine – Oklahoma State University. He completed a Fellowship in Endocrinology, Metabolism and Hypertension at the University of Oklahoma in Oklahoma City. Dr. Hanson’s Internal Medicine Residency and Rotating Internship were completed at Tulsa Regional Medical Center. He received his medical degree from Oklahoma State University and his Bachelor of Science degree from Northeastern Oklahoma State University in Tahlequah. Board certified in Internal Medicine, Endocrinology, Diabetes and Metabolic Diseases

Rebecca L. Smith, MD, FACC
Dr. Smith is a noninvasive cardiologist with subspecialty expertise in transthoracic echocardiography, transesophageal echocardiography, intraoperative echocardiography, stress and pharmacological echocardiography and contrast echocardiography. She completed an Advanced Cardiac Imaging Fellowship at the Cleveland Clinic Foundation and her Cardiology Fellowship at the University of New Mexico Health Sciences Center, Albuquerque, NM. Dr. Smith’s Internal Medicine Internship and Residency training were performed at the University of Arizona Health Sciences Center in Tucson. She received her medical degree from the Medical College of Ohio. Dr. Smith completed her Bachelor of Science degree at Cleveland State University. Board certified in Internal Medicine, Cardiovascular Disease and Echocardiography

Tobie L. Bresloff, MD
Dr. Bresloff is a specialist in Endocrinology, Metabolism and Hypertension, with expertise in diabetes, lipids, hypertension and thyroid diseases. She also serves as Assistant Professor in Clinical Medicine at the University of Oklahoma College of Medicine - Tulsa and Chief Quality Officer at Hillcrest Medical Center. She completed an NIH Fellowship in Endocrinology and Metabolism at Vanderbilt University in Nashville, TN. Dr. Bresloff’s Internal Medicine Internship and Residency were completed at Sinai Hospital of Detroit, Detroit, MI. She received her medical degree from Wayne State University School of Medicine in Detroit and her Master of Science and Bachelor of Science degrees at the University of Michigan, Ann Arbor, MI.

David A. Sandler, MD, FACC
Dr. Sandler is a cardiologist with subspecialty expertise in electrophysiology, complex ablation, and atrial fibrillation management. He completed his Cardiac Electrophysiology Fellowship and his Cardiovascular Medicine Fellowship at New York University Medical Center, New York, NY. Dr. Sandler’s Internal Medicine Internship and Residency were performed at Mount Sinai Medical Center, New York, NY. He earned his medical degree from Georgetown University School of Medicine in Washington, DC. Dr. Sandler received his Bachelor of Arts degree at the University of Pennsylvania in Philadelphia. Board certified in Internal Medicine, Cardiovascular Disease and Cardiac Electrophysiology

Raj H. Chandwaney, MD, FACC, FSCAI
Dr. Chandwaney is an interventional cardiologist with expertise in cardiac catheterization, coronary angioplasty and related interventional procedures such as coronary stents, atherectomy, intravascular ultrasound and peripheral vascular interventional procedures. He completed his Clinical Cardiology Fellowship at Northwestern University Medical School in Chicago, IL, where he also completed an Interventional Cardiology Fellowship. Dr. Chandwaney’s Internal Medicine Internship and Residency were performed at Baylor College of Medicine in Houston, TX. He received his medical degree from the University of Illinois at Chicago. Dr. Chandwaney completed his Master of Science degree at the University of Illinois at Urbana-Champaign, where he also received his Bachelor of Science degree.

Board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Endovascular Medicine

D. Erik Aspenson, MD, FACE, FACP
Dr. Aspenson is a specialist in Endocrinology, Metabolism and Hypertension at Oklahoma Heart Institute, with expertise in diabetes, lipids, hypertension and thyroid diseases. He completed a fellowship in Endocrinology at Wilford Hall Medical Center, Lackland AFB, Texas. Dr. Aspenson’s Internal Medicine Internship and Residency were completed at David Grant Medical Center, Travis AFB, California where he served as Chief Resident. He received his medical degree from the University of Oklahoma and his Bachelor of Science degree at Oklahoma State University.

Board certified in Internal Medicine, Endocrinology and Metabolic Diseases

Frank J. Gaffney, MD, FACC
Dr. Gaffney is an invasive and noninvasive cardiologist with subspecialty expertise in transesophageal echocardiography, nuclear cardiology, and coronary angiography. He completed his Cardiovascular Medicine Fellowship at Scott & White Memorial Hospital in Temple, Texas. Dr. Gaffney completed his Internal Medicine Internship and Residency at Brooke Army Medical Center in San Antonio. He then remained on staff at Scott & White Memorial Hospital for several years, before entering his Fellowship in Cardiovascular Medicine. Dr. Gaffney earned his medical degree from New York Medical College, Valhalla, New York, and he received his Bachelor of Arts degree at Hofstra University in Hempstead, New York.

Board certified in Internal Medicine, Cardiovascular Disease and Nuclear Cardiology

Eric G. Auerbach, MD, FACC
Dr. Auerbach is a specialist in magnetic resonance imaging, nuclear cardiology, cardiac computed tomography, echocardiography, stress echocardiography and transesophageal echocardiography. He completed his Cardiovascular Magnetic Resonance Imaging fellowship at Oklahoma Heart Institute, Tulsa, OK. His Cardiology fellowship was performed at the University of Miami/Jackson Memorial Hospital in Miami, FL. Dr. Auerbach’s Internal Medicine Internship and residency were also
completed at the University of Miami/Jackson Memorial Hospital in Miami. Prior to that, he performed a Surgery Internship at New York Hospital/ Cornell Medical Center, New York, NY. Dr. Auerbach earned his medical degree at the University of Miami School of Medicine, Miami, Florida and his Bachelor of Arts degree at Princeton University, Princeton, New Jersey. Board certified in Internal Medicine, Cardiovascular Disease and Nuclear Cardiology

Kelly R. Flesner, MD
Dr. Flesner-Gurley is a specialist in Endocrinology, Metabolism and Hypertension at Oklahoma Heart Institute, with expertise in diabetes, lipids, hypertension and thyroid diseases. Prior to joining Oklahoma Heart, she was at St. John Medical Center in Tulsa. She completed her fellowship in Endocrinology at the University of Texas at Galveston. Her Internal Medicine Internship and Residency were completed at the University of Texas in Houston, where she also received her medical degree. She earned her Bachelor of Science degree at Texas A&M University in College Station, TX. Board certified in Internal Medicine, Endocrinology, Diabetes and Metabolic Diseases

Robert L. Smith, Jr., MD, MSc, FACC, FSCAI
Dr. Smith specializes in interventional cardiology including cardiac catheterization, coronary angioplasty and related interventional procedures such as coronary stents, atherectomy, intravascular ultrasound and peripheral vascular interventional procedures. He completed an Interventional Cardiology Fellowship at Vanderbilt University School of Medicine in Nashville, TN and Tulane University School of Medicine in New Orleans. He received his medical degree from the University of Oklahoma College of Medicine in Oklahoma City and then completed his Internal Medicine Internship and Residency at Emory University School of Medicine in Atlanta, GA. Dr. Smith received his Bachelor of Science, Bachelor of Arts, and Master of Science degrees at the University of Oklahoma in Norman, OK. Board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Nuclear Cardiology

Craig S. Cameron, MD, FACC
Dr. Cameron is a cardiologist with subspecialty expertise in electrophysiology, including the implantation and management of cardiac pacemakers, defibrillators, and cardiac resynchronization devices, as well as catheter ablation. He completed his Cardiac Electrophysiology Fellowship and his Cardiovascular Disease Fellowship at Baylor University Medical Center in Dallas, TX. Dr. Cameron’s Internship and Internal Medicine Residency were performed at Baylor College of Medicine in Houston. He earned his medical degree from the University of Kansas School of Medicine in Kansas City, KS. Dr. Cameron received his Bachelor of Science degree at Pittsburg State University in Pittsburg, KS. Board certified in Internal Medicine and Cardiovascular Disease

Eugene J. Ichinohe, MD, FACC
Dr. Ichinohe specializes in interventional cardiology including cardiac catheterization, coronary angioplasty and related interventional procedures such as coronary stents, atherectomy, intravascular ultrasound and peripheral vascular interventional procedures. He earned his Bachelor of Science degree from Texas Christian University in Fort Worth, TX and his medical degree from Louisiana State University in New Orleans. He then completed his Internal Medicine residency, general cardiology and interventional cardiology fellowships at the University of Massachusetts Memorial Health Care Center in Worcester, MA. Board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Nuclear Cardiology

Cristin M. Bruns, MD
Dr. Bruns is a specialist in endocrinology, diabetes and metabolism at Oklahoma Heart Institute, with expertise in diabetes, thyroid disease (including thyroid cancer) and polycystic ovary syndrome. She completed her Internal Medicine Internship and Residency and Endocrinology Fellowship at the University of Wisconsin Hospital and Clinics in Madison, WI. Dr. Bruns earned her medical degree from Saint Louis University School of Medicine in St. Louis, MO and her Bachelor of Arts and Bachelor of Science degrees in biology from Truman State University in Kirksville, MO. Prior to joining Oklahoma Heart Institute, Dr. Bruns worked as a clinical endocrinologist at the Dean Clinic in Madison, Wisconsin. Board certified in Internal Medicine, Endocrinology, Diabetes and Metabolic Diseases

Gregory A. Cogert, MD
Dr. Cogert is a cardiologist who specializes in electrophysiology, including catheter ablation of arrhythmia, as well as the implantation and management of cardiac pace-makers, defibrillators, and cardiac resynchronization devices. He completed his Cardiac Electrophysiology Fellowship at Mayo Clinic in Rochester, MN and his Cardiovascular Fellowship at Cedars-Sinai Medical Center in Los Angeles, CA. Dr. Cogert’s Internal Medicine Internship and Residency were completed at UCLA Medical Center in Los Angeles. He earned his medical degree from the University of California in Irvine and received his Bachelor of Science degree in microbiology and molecular genetics from the University of California in Los Angeles. Board certified in Internal Medicine, Cardiovascular Disease, Echocardiography and Nuclear Cardiology

John S. Tulloch, MD
Dr. Tulloch is a noninvasive cardiologist with expertise in adult echocardiography, peripheral vascular imaging, nuclear cardiology, cardiac computed tomography and MRI. He completed his Cardiovascular Fellowship at the University of Kansas Medical Center in Kansas City, KS. Dr. Tulloch’s Internal Medicine Internship and Residency also were completed at the University of Kansas Medical Center. He earned his medical degree from Ross University School of Medicine in New Brunswick, NJ and received his Bachelor of Science degree in biology from Avila University in Kansas City, MO. Board certified in Internal Medicine

Anthony W. Haney, MD
Dr. Haney is a noninvasive cardiologist with expertise in nuclear cardiology, echocardiography, peripheral vascular imaging, cardiac computed tomography and MRI. He completed his Cardiovascular Fellowship at the Medical College of Virginia in Richmond. Dr. Haney’s Internal Medicine Internship and Residency were completed at the Mayo Clinic in Scottsdale, AZ. He earned his medical degree from the University of Oklahoma School of Medicine. Board certified in Internal Medicine, Cardiovascular Disease and Nuclear Cardiology
extent of disease in the superficial systems, doing away with the retrograde flow at the sapheno-femoral junction alone (by removing the greater saphenous vein) will provide dramatic clinical results in most patients. The offending greater saphenous vein is removed, the superficial blood it collects reroutes and finds alternative pathways directly into the deep system, and the stress on the superficial system is alleviated. If not altogether reversed. With removal of a diseased greater saphenous vein, varicosities often shrink, edema improves, and skin changes and ulcers begin to heal. For patients who fail to experience complete relief from removal of the greater saphenous vein, a host of other treatments are available, including removal of persistent varicosities through tiny incisions under local anesthesia (stab phlebectomies), basis under local anesthesia with good results.

During the last several years, less invasive alternatives to surgical vein stripping procedures have been developed, and have targeted treatment of greater saphenous and small saphenous veins. Endovenous laser ablation and radiofrequency ablation of diseased greater and small saphenous veins have largely replaced the more painful surgical procedures. In several trials, these minimally invasive procedures, which can be performed on an outpatient basis, have proven to be as effective as the surgical alternatives, while laser endovenous ablation of the greater saphenous vein and radio-frequency ablation of the greater saphenous vein are both as effective as surgery, radiofrequency ablation causes the least amount of patient discomfort, and is emerging as the minimally invasive procedure of choice.

During radiofrequency ablation of the greater saphenous vein, a tiny incision is made near the knee (Figure 5). Under ultrasound guidance, the greater saphenous vein is cannulated and a radiofrequency ablation catheter is advanced from the knee to the sapheno-femoral junction near the groin. Radiofrequency waves are then applied to the vein, causing the vein to fibrose and permanently close (Figure 6). In a matter of minutes, the vein is ablated, and the same functional outcome of the more painful surgical treatments is achieved. Although the benefit to the patients is the same as the surgical approach, patients may have this procedure performed on an outpatient basis and will walk out of the office afterward, often experiencing dramatic results in hours to days after the procedure. When done properly, radiofrequency ablation of the saphenous vein is associated with little pain, speedy recovery time, and lasting results. Complications, which include infection, paresthesias, DVT/PE, skin burns, and lymphedema, are exceedingly rare.

Several clinical scenarios may lead to the recommendation of minimally invasive saphenous vein ablation, but the presence of reflux must be confirmed by ultrasound prior to consideration of any treatment. Venous duplex and mapping studies are performed in order to rule out deep venous thrombosis in the deep venous

continued on page 16
Venous reflux disease results in painful and cosmetically displeasing derangements of normal venous anatomy. At the extreme, it leads to recalcitrant venous ulcers, which can themselves cause secondary health issues. In the modern era, this common disease can be effectively treated with a minimally invasive, office-based procedure, with pleasing results (Figure 7). Radiofrequency saphenous vein ablation results in less discomfort and risk to the patient than surgical alternatives, and is proven to have lasting benefit.

REFERENCES
PRASUGREL: A New Third-Generation Thienopyridine

DUAL ANTIPLATELET THERAPY

with aspirin and thienopyridine is a crucial element of treatment to prevent thrombotic complications in acute coronary syndromes and in percutaneous coronary interventions. Thienopyridines inhibit platelet aggregation, increase bleeding time and reduce blood viscosity by inhibiting adenosine diphosphate (ADP) action on platelet receptors. They inhibit the binding of ADP to the P2Y12 component of the ADP receptor (Figure 1). Blockade of this receptor inhibits ADP-induced platelet activation and subsequent platelet aggregation, and also decreases platelet activation by other outside stimuli.

Ticlopidine (Ticlid), clopidogrel (Plavix) and prasugrel (Effient) are the three available thienopyridines that are used in clinical practice. Ticlopidine (Ticlid) was the first thienopyridine used in the stent era, but was associated with a high rate of gastrointestinal side effects and bone marrow suppression.

Ticlopidine is associated with neutropenia, thrombocytopenia, and in one percent of cases with TTP which can be fatal in 25-40 percent of cases. Thus, a CBC should be checked every two weeks while on ticlopidine. In the past few years, ticlopidine has been used only on rare occasions, mostly in patients who are allergic to clopidogrel.

Clopidogrel (Plavix) was developed to avoid the hematological complications associated with ticlopidine. In clinical trials, clopidogrel has not been associated with an increased incidence of these hematological side effects. Clopidogrel quickly replaced ticlopidine as the preferred thienopyridine in the late 1990s. There are several limitations to clopidogrel therapy, including significant interpatient variability of effectiveness and a delayed onset of action.

Despite treatment with dual anti-platelet therapy, a significant percentage of patients have recurrent thrombotic events. Patients with a reduced pharmacological response to clopidogrel are at an increased risk for coronary stent thrombosis and myocardial infarction. Coronary stent thrombosis can be a devastating complication with mortality rates ranging from 32-45% in patients with drug-eluting stent thrombosis. There is a significant genetic variability of pharmacological response to clopidogrel, which makes some patients less responsive to

continued on page 18
clopidogrel, increasing their risk for coronary stent thrombosis.

Prasugrel (Effient), a new third-generation thienopyridine, was recently approved by the FDA as an alternative to clopidogrel for the treatment of patients having percutaneous coronary intervention and acute coronary syndromes. Both clopidogrel and prasugrel are products requiring conversion to their active metabolite by liver enzymes; however, prasugrel uses a single, rather than a multiple-step process for activation, which provided a higher potency and a faster onset of action than clopidogrel. Prasugrel inhibits ADP-induced platelet aggregation more quickly, more consistently and to a greater degree than clopidogrel in patients with coronary artery disease.

The TRITON-TIMI-38 trial was designed to test the hypothesis that using an agent with a higher level of inhibition of ADP-induced platelet aggregation and a more consistent response than clopidogrel reduces ischemic events. TRITON-TIMI

Prasugrel, a new third-generation thienopyridine can be used as an alternative to clopidogrel in patients with acute coronary syndromes who are scheduled to have PCI.

38 enrolled 13,608 patients with acute coronary syndromes who were scheduled for PCI and were randomized to either prasugrel or clopidogrel. 26 percent of the patients had ST elevation MI and 74 percent had unstable angina or Non-ST elevation MI (Table 1). 94 percent of the patients received at least one coronary stent, and 47 percent received at least one drug-eluting stent. A loading dose of study medication (60mg of prasugrel or 300mg of clopidogrel) was given in a randomized, double blind manner followed by maintenance doses of prasugrel (10mg) or clopidogrel (75mg) daily (Figure 2).

The primary efficacy end point in the TRITON-TIMI 38 trial was a composite of the rate of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke during the follow-up period. Key secondary endpoints were stent thrombosis and a composite of death from cardiovascular causes, nonfatal MI and nonfatal stroke or rehospitalization for cardiac ischemia.
Key safety end points involved TIMI major or minor bleeding.

The results of the study demonstrated that 12.1 percent of the patients in the clopidogrel group had the primary endpoint, as compared to 9.9 percent in the prasugrel group (a 19 percent relative risk reduction and a 2.2 percent absolute risk reduction, which is highly statistically significant) (Table 2 and Figure 3). This difference was driven largely by a significant reduction in myocardial infarction in the prasugrel group (9.7 percent in the clopidogrel group vs 7.4 percent in the prasugrel group). The prasugrel group also had lower rates of urgent target vessel revascularization (3.7 percent vs 2.5 percent) and lower rates of stent thrombosis (2.4 percent vs 1.1 percent). Table 3 demonstrates hazard ratios and rates of the primary end point according to selected subgroups. The benefit of prasugrel is clearly greater in patients with diabetes than in those without diabetes.

Patients treated with prasugrel had a higher rate of TIMI major bleeding not related to CABG (2.4 percent in the prasugrel group vs 1.8 percent in the clopidogrel group). Patients who required CABG also had higher bleeding rates in the prasugrel group.
Subpopulations at increased risk for non-CABG bleeding included those patients less than 60 kg body weight and age 75 and above. Patients with a previous TIA or stroke had no evidence for clinical benefit from prasugrel as compared with clopidogrel and had a strong trend toward a greater rate of TIMI major bleeding, including an increase in intracranial hemorrhage.

The reduction in ischemic events by several well-established antiplatelet agents including aspirin, clopidogrel, and abciximab have been associated with increased rates of bleeding. Thus, it is not surprising the prasugrel has lower rates of ischemic events, and also higher rates of bleeding when compared with clopidogrel.

In the subgroup analysis of patients with unstable angina/Non-ST elevation MI, the patients demonstrating the most benefit from prasugrel compared to clopidogrel were the patients with diabetes mellitus, metabolic syndrome and previous MI (Figure 4).

Prasugrel has a black box warning. Prasugrel is contraindicated in patients with active pathological bleeding or in those with a propensity to bleed.

Prasugrel is not recommended in patients age 75 and older. Prasugrel is contraindicated in patients with a previous history of TIA or stroke. Prasugrel is not recommended in patients on coumadin or NSAIDS. Ideally, prasugrel should not be used.
in patients less than 60kg body weight. If it is used in these patients, a 5mg maintenance dosage is recommended. Ideally, the coronary anatomy should be known before initiating prasugrel because of the significant risk of bleeding associated with CABG. If CABG is needed, prasugrel should be stopped for at least seven days prior to CABG if possible. If bleeding occurs, platelets can be given; however platelet transfusions within six hours of the loading dose or four hours of the maintenance dose may be less effective.

In summary, prasugrel can be used as an alternative to clopidogrel in patients with acute coronary syndromes who are scheduled to have PCI. Certain high risk patients, such as those with diabetes, metabolic syndrome and previous MI who are greater then 60kg in body weight and less than age 75 are the patients who are most likely to receive greater benefit with prasugrel as compared to clopidogrel. This difference is driven primarily by a reduction in nonfatal MI. Prasugrel is contraindicated in patients with a previous history of TIA or stroke.

REFERENCES
3 Steinhubl SR, Berger PB et al. Early and sustained dual oral ant platelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
5 Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007;5:45-55

Dr. Greg Johnsen is an interventional cardiologist with expertise in cardiac catheterization, angioplasty and related interventional procedures, such as stents and atherectomy.
THE REASON FOR THIS is that most people only think of habits as something bad. If you ask ten people on the street what the word habit means, nine out of ten will tell you that a habit is a negative action that people do over and over again, like smoking, or procrastinating or eating too much. But the truth is that positive habits hold the keys to success in virtually everything you do. What are positive habits you ask? A positive habit is simply a habit that produces positive benefits, action and attitudes. Why is there such great power in positive habits to effect change? Because habits, by their very nature, are automatic, and after a period of time they can also become permanent. This is a very powerful combination.

So how do we go about adding new positive habits to our life? It’s really quite easy. You simply begin repeating an action, attitude or thought process every day for at least 21 days. Research has shown that an action that is repeated for a minimum of 21 days is likely to become a permanent habit.

Remember that positive habits have positive benefits and you will reap those benefits for as long as you maintain that habit. So now that we know what positive habits are, and how to acquire them, let’s look at some simple positive habits for success.
POSITIVE HABIT #1 – Make it a Habit to Set Goals
Did you know that the most successful people all share the common positive habit of goal setting? A study was done to determine the importance of goal setting. College students who had gone on to achieve great success in business were asked to list their habits. The students who had made a habit of setting goals were in the top 3 percent of earnings in the population! It is almost impossible to overestimate the value of goal-setting as a positive habit. Goal setting is simple, yet 97 percent of the population never do it. By making goal setting a positive habit, you can start placing yourself in the top 3 percent of the population of successful people.

Remember that positive habits have positive benefits and you will reap those benefits for as long as you maintain that habit. So now that we know what positive habits are, and how to acquire them, let’s look at some simple positive habits for success.

Here are some steps to help you make goal setting a positive habit:
Step 1. Define your goals, write them down, and be very specific; capture your goals on paper. It is amazing how many people never take the time to write down exactly what it is they want in life. Remember, you can’t hit a target if you don’t have one.
Step 2. Determine what the time line is for reaching your goals; set specific deadlines for each goal.
Step 3. Identify any obstacles that may stand in your way, list them, and state how you plan to overcome them.
Step 4. Make a list of the people and/or organizations who will help you reach your goals.

Delegate it. Give the task to someone else. This is a very critical aspect of time management. Your time is valuable; make it a habit to work on tasks that you do best and delegate the tasks that can be performed by someone else.

POSITIVE HABIT #2 – Be more Productive with the 4-D Habit
May of us are stressed out by the negative effects of work overload in our careers. The 4-D habit is a very simple positive habit that will help you to prevent work overload. Every time you are faced with a new task to perform, apply the 4-Ds as listed below. You will find that your workload will be reduced as you apply this screening and decision making tool to each task you are confronted with. Decide on the most appropriate choice — and take action.

Do it Now. Take immediate action, do the task right away, don’t procrastinate.
Dump it Now. Make a quick decision and dump the task.

POSITIVE HABIT #3 – Create and Repeat Positive Attitude Phrases
A positive attitude is perhaps the most important ingredient to success and a surefire way to maintain a positive attitude is to make a habit to repeat positive attitude phrases. Choose or create a positive attitude phrase and repeat it aloud many times each day. In a few days you will notice that your attitude will become more positive. Here are some examples:

- “I am reaching my success goals every day.”
- “I am getting stronger and stronger every day.”
- “I can overcome any obstacle.”
- “Every day I am getting closer and closer to my goals in life.”
- “If I believe it, I can achieve it.”
- “Every day, my mental attitude is becoming more positive.”

Positive habits can truly change your life, I know from personal experience. I am now constantly aware of the habits I have and the new positive habits I am acquiring;
HEARTFELT PERFORMANCES
PREMIERING DAILY AT OKLAHOMA HEART INSTITUTE

Every day we give it our best.
Placing life saving stents in heart attack patients. Restoring normal heartbeats to those whose abnormal rhythms prevent a simple daily walk. Using advanced screening tests to detect life-threatening blockages in seemingly healthy young adults.

Our team of 24 specialists is highly trained in all areas of cardiology and endocrinology.

For you, that means premier heart care from doctors with some of the best outcomes in the region. Isn’t that what you want when your heart is on the line?

HEARTFELT PERFORMANCES. DRAMATIC RESULTS. COMPASSIONATE CARE.

Trust your heart to the doctors of Oklahoma Heart Institute. Today’s leading name in cardiology.

Oklahoma Heart Institute

A Nationally Recognized Cardiovascular Institute

918.592.0999 / www.oklahomahart.com / 1120 S. UTICA AVENUE Oklahoma Heart Institute (The Heart Hospital)
1265 S. UTICA (Utica Physicians Office) / 9228 S. MINGO (SouthPointe Physician Offices)